Human medicines European public assessment report (EPAR): Ranibizumab Midas, ranibizumab, Date of authorisation: 19/09/2024, Status: Authorised
Joint HMA/EMA multi-stakeholder workshop on submission predictability, Online, European Medicines Agency, Amsterdam, the Netherlands, from 25 September 2024, 09:00 (CEST) to 25 September 2024, 13:30 (CEST)
Report - Joint HMA/EMA multi-stakeholder workshop on submission predictability
Linkedin Live session: A call to action against antimicrobial resistance , European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 11 November 2024, 11:30 (CET) to 11 November 2024, 12:30 (CET)
Norditropin (somatropin) supply shortage
European Medicines Agency’s data protection notice use of personal data as part of the emergency mass notification system
European Medicines Agency’s data protection notice for the European Union (EU) Metadata Catalogue
European Medicines Agency's data protection notice for use of Microsoft Intune for personal and corporate-owned devices
European Medicines Agency's data protection notice for Microsoft Edge
European Medicines Agency's data protection notice for the Security Operation Centre (SOC)